

Terumo Revises the First-Half Results Forecast for FY 2017

TOKYO, JAPAN – October 19, 2017 – Terumo Corporation (TSE: 4543) today announced that it revised the first-half results forecast for the year ending March, 2018 (FY 2017).

1. First-half results forecast for FY 2017 (From April 1 to September 30, 2017)

	Net sales (Million yen)	Operating income (Million yen)	Ordinary income (Million yen)	Profit attributable to owners of parent (Million yen)	Net income per share (Yen)
Prior forecast	276,000	39,000	37,500	25,000	71.03
Revised forecast	284,000	47,000	46,000	32,000	90.91
Change	8,000	8,000	8,500	7,000	
Change (%)	2.9%	20.5%	22.7%	28.0%	
(Ref.) Results for the first-half of prior fiscal year	245,110	39,370	30,601	20,423	56.27

2. Reasons for the revision

Net sales, operating income, ordinary income, and profit attributable to owners of parent are expected to exceed the prior forecast due to the strong sales driven by Terumo Interventional Systems and Neurovascular businesses overseas.

3. Supplementation for full-year results forecast for FY 2017

As outlined in the "Terumo Provides Update on Impact from Hurricane Maria" announced on October 10, Terumo has been suspending its manufacturing of the Angio-Seal™ Vascular Closure product line since September 20 due to Hurricane Maria.

Though the impact of the disaster on Terumo's business performance of second-half is being examined, at this moment, we are not changing the full-year results forecast, since we anticipate achieving the full-year forecast even with the potential impact taken into account.

(Ref.) Full-year results forecast for FY 2017 (Announced on May 10, 2017)

	Net sales (Million yen)	Operating income (Million yen)	Ordinary income (Million yen)	Profit attributable to owners of parent (Million yen)	Net income per share (Yen)
Prior forecast	575,000	82,000	79,500	53,000	150.58
Results for the prior fiscal year	514,164	76,578	68,552	54,225	150.15

About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over \$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

Disclaimer

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.

###